1H NMR (500 MHz, CDCl3): d 5.97 (d, 1H, 2JHH = 17 Hz,
NCHHCHQCH2, not coordinated), 5.78 (m, 1H, NCH2CHQ
CH2, not coordinated), 5.08 (m, 1H, NCH2CHQCH2, not
coordinated), 4.68 (m, 2H, NCH2CHQCH2, not coordi-
nated), 4.46 (m, 1H, NCHHCHQCH2, not coordinated),
3JHH = 5.0 Hz, 2JHH = 13.0 Hz, 2H, NCHHCHQCH2), 4.40
2
(d, 2H, JHH = 13.5 Hz, NCHHCHQCH2), 3.52 (m, 2H,
COD), 3.47 (d, 3JHH = 9.0 Hz, 2H, NCH2CHQCHHcis), 2.85
3
(m, 2H, COD), 2.75 (d, JHH
=
11.5 Hz, 2H,
NCH2CHQCHHtrans), 2.72 (m, 2H, COD), 2.29 (m, 4H,
COD). 13C NMR (75 MHz, CDCl3): d NCN not observed,
120.6 (NCHCHN), 93.7, 74.0 (COD), 64.9 (NCH2CHQCH2),
51.6 (NCH2CHQCH2), 42.6 (NCH2CHQCH2), 32.8, 31.4
(COD). ESI-MS (cone 25 V): m/z (fragment) 449.1 [M]+.
4.13 (m, 2H, NCHHCHQCH2, coordinated and
= 11 Hz,
2
NCH2CHCH2, coordinated), 3.77 (d, JHH
NCHHCHQCH2, coordinated), 3.59 (m, 1H, COD), 3.46
(m, 1H, COD), 3.34 (m, 1H, COD), 2.87 (m, 2H, COD),
2.68 (m, 1H, COD), 2.38 (m, 2H, COD), 2.28 (m, 1H,
NCH2CHQCHH, coordinated), 2.00 (m, 2H, COD), 1.91
(m, 1H, NCH2CHQCHH), 1.58 (m, 2H, COD).
4,5-Dichloro-1,3-bis(2-propenyl)imidazolin-2-ylidene [(1,2,5,6-g)-
.
1-5-cyclooctadiene]iridium hexafluorophosphate (2b PF6). The
13C NMR (75 MHz, CDCl3): d 161.61 (NCN), 134.05
(NCH2CHQCH2, not coordinated), Cl–C not observed,
115.87 (NCH2CHQCH2, not coordinated), 99.41, 97.96,
61.20, 56.06 (COD–CH), 52.36 (NCH2CHQCH2, coordi-
nated), 50.55 (NCH2CHQCH2, not coordinated), 44.55
(NCH2CHQCH2, coordinated), 40.96 (COD–CH2), 35.54
(NCH2CHQCH2, coordinated), 33.15, 28.80, 27.48 (COD).
ESI-MS (cone 25 V): m/z (fragment) 517.1 [M ꢁ Cl]+.
synthesis of complex 2b was carried out using the same general
procedure as described for complex 2a but followed by anion
exchange (PF6ꢁ) using complex 1b (75 mg, 0.13 mmol) and
AgBF4 (25 mg, 0.13 mmol) (yield 68 mg, 92%).
1H NMR (500 MHz, CDCl3):
NCH2CHQCH2), 4.91 (m, 2H, COD), 4.55 (dd, JHH = 4.5
Hz, 2JHH = 13.5 Hz, 2H, NCHHCHQCH2), 4.35 (d, 2JHH
d
5.22 (m, 2H,
3
=
13.0 Hz, 2H, NCHHCHQCH2), 3.59 (m, 2H, COD), 3.51 (d,
3JHH = 6.5 Hz, 2H, NCH2CHQCHHcis), 2.88 (d, 3JHH = 10
Hz, 2H, NCH2CHQCHHtrans), 2.86 (m, 2H, COD), 2.73 (m,
2H, COD), 2.26 (m, 4H, COD). 13C NMR (125 MHz,
4,5-Dimethyl-1,3-bis(2-propenyl)imidazolin-2-ylidene [(1,2,5,6-g)-
1-5-cyclooctadiene]chloro iridium (1c). The synthesis of com-
plex 1c was carried out using the same general procedure as
described for complex 1a using silver oxide (94 mg, 0.45
mmol), 4,5-dimethyl-1,3-bis(2-propenyl)imidazolium chloride
(95 mg, 0.45 mmol) and [IrCl(COD)]2 (150 mg, 0.22 mmol)
(yield 148 mg, 66%).
acetone):
d 161.25 (NCN), 114.6 (Cl–C), 94.82, 74.53
(COD), 63.71 (NCH2CHQCH2), 51.11 (NCH2CHQCH2),
42.60 (NCH2CHQCH2), 32.26, 30.87 (COD). ESI-MS (cone
25 V): m/z (fragment) 517.0 [M]+.
4,5-Dimethyl-1,3-bis(2-propenyl)imidazolin-2-ylidene [(1,2,5,6-g)-
1-5-cyclooctadiene]iridium hexafluorophosphate (2cPF6). The
synthesis of complex 2c was carried out using the same general
procedure as deꢁscribed for complex 2a but followed by anion
exchange (PF6 using complex 1c (40 mg, 0.08 mmol) and
AgBF4 (15 mg, 0.08 mmol) (yield 30 mg, 68%).
1H NMR (500 MHz, CDCl3):
d
5.85 (m, 2H,
NCHHCHQCH2, NCH2CHQCH2, not coordinated), 5.03
2
(d, JHH = 15.5 Hz, 1H, NCH2CHQCH2, not coordinated),
4.60 (m, 1H, NCH2CHQCH2, not coordinated), 4.18 (m, 2H,
COD, NCHHCHQCH2, not coordinated), 4.01 (m, 2H,
NCHHCHQCH2, coordinated and COD), 3.61–3.43 (m,
4H, NCHHCHQCH2, NCH2CHQCH2, coordinated and
COD), 3.30 (m, 1H, COD), 2.95 (m, 2H, COD), 2.85 (m,
2H, COD), 2.38 (m, 1H, COD), 2.28 (m, 1H,
NCH2CHQCHH, coordinated), 2.06 (s, 3H, CH3), 1.91 (m,
1H, NCH2CHQCHH, coordinated), 1.89 (s, 3H, CH3), 1.54
(m, 2H, COD). 13C NMR (75 MHz, CDCl3): d 158.9 (NCN),
136.1 (NCH2CHQCH2, not coordinated), 125.8 (C–CH3),
122.2 (C–CH3), 114.5 (NCH2CHQCH2, not coordinated),
98.3, 96.7, 60.1, 55.3 (COD), 50.3 (NCH2CHQCH2, coordi-
nated), 49.4 (NCH2CHQCH2, not coordinated), 46.1
1H NMR (500 MHz, CDCl3):
NCH2CHQCH2), 4.74 (m, 2H, COD), 4.44 (dd, JHH = 4.5
Hz, 2JHH = 13.0 Hz, 2H, NCHHCHQCH2), 4.21 (d, 2JHH
d
5.17 (m, 2H,
3
=
12.5 Hz, 2H, NCHHCHQCH2), 3.47 (m, 2H, COD), 3.44 (d,
3JHH = 8.0 Hz, 2H, NCH2CHQCHHcis), 2.85 (m, 2H, COD),
2.77 (d, 3JHH = 12.0 Hz, 2H, NCH2CHQCHHtrans), 2.70 (m,
2H, COD), 2.29 (m, 4H, COD), 1.98 (s, 6H, CH3). 13C NMR
(125 MHz, CDCl3): d NCN not observed, 124.7 (C–CH3),
93.3, 74.2 (COD), 63.9 (NCH2CHQCH2), 49.2 (NCH2CH
QCH2), 42.2 (NCH2CHQCH2), 32.7, 31.3 (COD), 9.4 (CH3).
ESI-MS (cone 25 V): m/z (fragment) 477.3 [M]+.
(NCH2CHQCH2,
coordinated),
41.2
(COD),
35.8
(NCH2CHQCH2, coordinated), 33.3, 29.0, 27.5 (COD), 9.7
(CH3), 8.9 (CH3). ESI-MS (cone 25 V): m/z (fragment) 477.2
[M ꢁ Cl]+.
1,3-Bis(4-pentenyl)-imidazolin-2-ylidene
[(1,2,5,6-g)-1-5-
cyclooctadiene]chloro iridium (3). Silver oxide (63 mg, 0.27
mmol) was added to a solution of 1,3-bis(4-pentenyl) imida-
zolium bromide (85 mg, 0.30 mmol) in MeOH. The mixture
was stirred at room temperature for 1 h and filtered through
Celites. The solution was concentrated under reduced pres-
sure and redissolved in dichloromethane. [IrCl(COD)]2 (100
mg, 0.15 mmol) was added and the mixture was stirred for 1 h
at 45 1C. The volatiles were removed under reduced pressure.
Compound 3 was obtained as a yellow oil (yield 122 mg, 77%).
1H NMR (500 MHz, CDCl3): d 6.83 (s, 2H, CH imidazole),
5.86 (m, 2H, –CHQCH2), 5.14 (m, 4H, –CHQCH2), 4.58
(s, 2H, COD), 4.36 (m, 2H, –NCH2–), 4.30 (m, 2H, –NCH2–),
2.88 (s, 2H, COD), 2.19 (m, 4H, COD), 2.0 (m, 4H, COD),
1,3-Bis(2-propenyl)-imidazolin-2-ylidene
[(1,2,5,6-g)-1-5-
cyclooctadiene]iridium tetrafluoroborate (2a). To a solution of
complex 1a (44 mg, 0.09 mmol) in acetone was added AgBF4
(18 mg, 0.09 mmol), and the mixture was stirred at room
temperature for 4 h. The suspension was filtered through
Celites and the solution concentrated under reduced pressure.
Precipitation with diethyl ether (6 mL) afforded a solid (yield
40 mg, 82%).
1H NMR (500 MHz, CDCl3): d 6.88 (s, 2H, NCHCHN),
5.19 (m, 2H, NCH2CHQCH2), 4.73 (m, 2H, COD), 4.60 (dd,
ꢀc
This journal is the Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2008
124 | New J. Chem., 2008, 32, 120–126